Insmed Reports 2025 Financial Results and 2026 Revenue Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy INSM?
Source: PRnewswire
- 2026 Revenue Expectations: Insmed anticipates that revenues from BRINSUPRI® (brensocatib) will reach at least $1 billion in 2026, while reiterating guidance for ARIKAYCE® (amikacin liposome inhalation suspension) revenues between $450 million and $470 million, reflecting strong confidence in the market potential of its new drugs.
- 2025 Financial Performance: The company reported total revenues of $606.4 million for 2025, with BRINSUPRI generating $144.6 million in Q4 and $172.7 million for the full year, while ARIKAYCE achieved $119.2 million in Q4 and $433.8 million for the year, marking a 19% annual growth that exceeded guidance, indicating robust market demand.
- Clinical Trial Progress: Insmed noted that clinical trials for BRINSUPRI and ARIKAYCE are progressing well, particularly the Phase 3 trials for TPIP, which are expected to lay the groundwork for future product expansions and enhance the company's competitive position in the market.
- Cash Flow and Investment Plans: As of the end of 2025, Insmed reported approximately $1.4 billion in cash and cash equivalents, demonstrating strong financial health, with plans to continue investing in the commercialization of BRINSUPRI and ARIKAYCE, supporting its future growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 149.330
Low
162.00
Averages
219.50
High
263.00
Current: 149.330
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
Insmed's Q4 Update Boosts Confidence in Brinsupri Launch Trajectory
- Confidence in Launch: Insmed's Q4 update highlights the progress of Brinsupri's market launch, indicating strong confidence in the product's trajectory, which is expected to drive future revenue growth for the company.
- Market Demand Expectations: With supportive clinical data for Brinsupri, Insmed anticipates attracting more patients, thereby solidifying its market position in the relevant therapeutic area.
- Financial Performance Outlook: Although specific financial figures were not disclosed, Insmed's update suggests a positive revenue inflow in the upcoming quarters, bolstering investor confidence.
- Strategic Development Focus: Insmed's Q4 update reflects not only confidence in Brinsupri but also the company's ongoing commitment to investment and innovation in the biopharmaceutical sector, aiming to address unmet medical needs.
See More
US Stocks Close Lower Amid AI Outlook Concerns
- Market Weakness: The S&P 500 index fell by 0.28%, the Dow Jones Industrial Average decreased by 0.54%, and the Nasdaq 100 index dropped by 0.41%, indicating market concerns over the outlook for artificial intelligence, particularly affecting chipmakers and AI infrastructure stocks.
- Mixed Economic Data: Initial jobless claims in the US fell to 206,000, a 5-week low, indicating a strong labor market; however, the December trade deficit widened to $70.3 billion, exceeding expectations, reflecting uncertainties in economic recovery.
- Shifts in Fed Policy Expectations: Hawkish comments from Fed officials suggest a potential need for interest rate hikes to combat persistent inflation, leading to a more hawkish outlook for future rate paths, which further dampens market sentiment.
- Earnings Season Nearing Conclusion: With over three-quarters of S&P 500 companies reporting, 74% exceeded expectations, and Q4 earnings are projected to grow by 8.4%, demonstrating corporate resilience, yet the market remains cautious about future growth prospects.
See More
Insmed Q4 2025 Earnings Call Highlights
- BRINSUPRI Revenue Guidance: Insmed anticipates BRINSUPRI revenue to exceed $1 billion in 2026, reflecting strong confidence in market access and early performance feedback, thereby establishing a solid foundation for future revenue growth.
- Significant ARIKAYCE Growth: In 2025, ARIKAYCE achieved a remarkable 40% growth in Japan, contributing over a quarter of global revenues, demonstrating the company's strong market performance in the region and providing excellent opportunities for future market expansion.
- Positive Cash Flow Outlook: The CFO reported a cash position of approximately $1.4 billion at the end of 2025, with expectations to achieve cash flow positivity without needing additional capital, enhancing the company's flexibility for future business development.
- Market Expansion Strategy: Management emphasized the potential to further expand BRINSUPRI's market by identifying undiagnosed bronchiectasis patients within the COPD and asthma populations, which is expected to drive overall company revenue to double in 2026.
See More
Insmed Reports 2025 Financial Results and 2026 Revenue Guidance
- 2026 Revenue Expectations: Insmed anticipates that revenues from BRINSUPRI® (brensocatib) will reach at least $1 billion in 2026, while reiterating guidance for ARIKAYCE® (amikacin liposome inhalation suspension) revenues between $450 million and $470 million, reflecting strong confidence in the market potential of its new drugs.
- 2025 Financial Performance: The company reported total revenues of $606.4 million for 2025, with BRINSUPRI generating $144.6 million in Q4 and $172.7 million for the full year, while ARIKAYCE achieved $119.2 million in Q4 and $433.8 million for the year, marking a 19% annual growth that exceeded guidance, indicating robust market demand.
- Clinical Trial Progress: Insmed noted that clinical trials for BRINSUPRI and ARIKAYCE are progressing well, particularly the Phase 3 trials for TPIP, which are expected to lay the groundwork for future product expansions and enhance the company's competitive position in the market.
- Cash Flow and Investment Plans: As of the end of 2025, Insmed reported approximately $1.4 billion in cash and cash equivalents, demonstrating strong financial health, with plans to continue investing in the commercialization of BRINSUPRI and ARIKAYCE, supporting its future growth strategy.
See More
Insmed Reports 2025 Financials and 2026 Revenue Guidance
- 2025 Revenue Performance: Insmed reported total revenues of $606.4 million for 2025, reflecting a 67% increase from 2024, with ARIKAYCE generating $433.8 million, a 19% year-over-year growth that exceeded the upper end of guidance, indicating strong market demand and product acceptance.
- BRINSUPRI Sales Outlook: The company anticipates at least $1 billion in revenues from BRINSUPRI (brensocatib) in 2026, showcasing its robust growth potential in the non-cystic fibrosis bronchiectasis market, further solidifying its leadership in respiratory disease treatments.
- R&D and Operating Expenses: Research and development expenses reached $771.1 million in 2025, a 29% increase from 2024, primarily driven by rising personnel costs and the acquisition of INS1148, indicating a commitment to innovation and the development of new therapies despite increased spending.
- Cash Flow and Financial Position: As of the end of 2025, Insmed held approximately $1.4 billion in cash and cash equivalents, ensuring ample funding for future R&D and market expansion, thereby enhancing its financial stability and competitive position in the market.
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
Insmed's Q4 Update Boosts Confidence in Brinsupri Launch Trajectory
- Confidence in Launch: Insmed's Q4 update highlights the progress of Brinsupri's market launch, indicating strong confidence in the product's trajectory, which is expected to drive future revenue growth for the company.
- Market Demand Expectations: With supportive clinical data for Brinsupri, Insmed anticipates attracting more patients, thereby solidifying its market position in the relevant therapeutic area.
- Financial Performance Outlook: Although specific financial figures were not disclosed, Insmed's update suggests a positive revenue inflow in the upcoming quarters, bolstering investor confidence.
- Strategic Development Focus: Insmed's Q4 update reflects not only confidence in Brinsupri but also the company's ongoing commitment to investment and innovation in the biopharmaceutical sector, aiming to address unmet medical needs.
See More
US Stocks Close Lower Amid AI Outlook Concerns
- Market Weakness: The S&P 500 index fell by 0.28%, the Dow Jones Industrial Average decreased by 0.54%, and the Nasdaq 100 index dropped by 0.41%, indicating market concerns over the outlook for artificial intelligence, particularly affecting chipmakers and AI infrastructure stocks.
- Mixed Economic Data: Initial jobless claims in the US fell to 206,000, a 5-week low, indicating a strong labor market; however, the December trade deficit widened to $70.3 billion, exceeding expectations, reflecting uncertainties in economic recovery.
- Shifts in Fed Policy Expectations: Hawkish comments from Fed officials suggest a potential need for interest rate hikes to combat persistent inflation, leading to a more hawkish outlook for future rate paths, which further dampens market sentiment.
- Earnings Season Nearing Conclusion: With over three-quarters of S&P 500 companies reporting, 74% exceeded expectations, and Q4 earnings are projected to grow by 8.4%, demonstrating corporate resilience, yet the market remains cautious about future growth prospects.
See More
Insmed Q4 2025 Earnings Call Highlights
- BRINSUPRI Revenue Guidance: Insmed anticipates BRINSUPRI revenue to exceed $1 billion in 2026, reflecting strong confidence in market access and early performance feedback, thereby establishing a solid foundation for future revenue growth.
- Significant ARIKAYCE Growth: In 2025, ARIKAYCE achieved a remarkable 40% growth in Japan, contributing over a quarter of global revenues, demonstrating the company's strong market performance in the region and providing excellent opportunities for future market expansion.
- Positive Cash Flow Outlook: The CFO reported a cash position of approximately $1.4 billion at the end of 2025, with expectations to achieve cash flow positivity without needing additional capital, enhancing the company's flexibility for future business development.
- Market Expansion Strategy: Management emphasized the potential to further expand BRINSUPRI's market by identifying undiagnosed bronchiectasis patients within the COPD and asthma populations, which is expected to drive overall company revenue to double in 2026.
See More
Insmed Reports 2025 Financial Results and 2026 Revenue Guidance
- 2026 Revenue Expectations: Insmed anticipates that revenues from BRINSUPRI® (brensocatib) will reach at least $1 billion in 2026, while reiterating guidance for ARIKAYCE® (amikacin liposome inhalation suspension) revenues between $450 million and $470 million, reflecting strong confidence in the market potential of its new drugs.
- 2025 Financial Performance: The company reported total revenues of $606.4 million for 2025, with BRINSUPRI generating $144.6 million in Q4 and $172.7 million for the full year, while ARIKAYCE achieved $119.2 million in Q4 and $433.8 million for the year, marking a 19% annual growth that exceeded guidance, indicating robust market demand.
- Clinical Trial Progress: Insmed noted that clinical trials for BRINSUPRI and ARIKAYCE are progressing well, particularly the Phase 3 trials for TPIP, which are expected to lay the groundwork for future product expansions and enhance the company's competitive position in the market.
- Cash Flow and Investment Plans: As of the end of 2025, Insmed reported approximately $1.4 billion in cash and cash equivalents, demonstrating strong financial health, with plans to continue investing in the commercialization of BRINSUPRI and ARIKAYCE, supporting its future growth strategy.
See More
Insmed Reports 2025 Financials and 2026 Revenue Guidance
- 2025 Revenue Performance: Insmed reported total revenues of $606.4 million for 2025, reflecting a 67% increase from 2024, with ARIKAYCE generating $433.8 million, a 19% year-over-year growth that exceeded the upper end of guidance, indicating strong market demand and product acceptance.
- BRINSUPRI Sales Outlook: The company anticipates at least $1 billion in revenues from BRINSUPRI (brensocatib) in 2026, showcasing its robust growth potential in the non-cystic fibrosis bronchiectasis market, further solidifying its leadership in respiratory disease treatments.
- R&D and Operating Expenses: Research and development expenses reached $771.1 million in 2025, a 29% increase from 2024, primarily driven by rising personnel costs and the acquisition of INS1148, indicating a commitment to innovation and the development of new therapies despite increased spending.
- Cash Flow and Financial Position: As of the end of 2025, Insmed held approximately $1.4 billion in cash and cash equivalents, ensuring ample funding for future R&D and market expansion, thereby enhancing its financial stability and competitive position in the market.
See More
